Sustained Skin Clearance
Recent long-term results from the Phase 3 Iconic-Advance 1 and 2 studies have unveiled compelling 52-week data regarding the efficacy of a new oral treatment
for moderate-to-severe plaque psoriasis. This therapy, a unique targeted oral peptide designed to specifically block the IL-23 receptor, has demonstrated remarkable sustained skin clearance. In the Iconic-Advance 1 trial, the proportion of patients achieving completely clear skin rose from 41% at Week 24 to an impressive 49% by Week 52. Similarly, the Iconic-Advance 2 trial showed a significant increase, with complete skin clearance rates escalating from 33% at Week 24 to a substantial 48% at the 52-week mark. These findings are particularly noteworthy as they indicate not just initial improvement, but a lasting effect over an entire year, reinforcing the potential of this therapeutic approach for patients seeking comprehensive skin restoration. The data was presented at the 2026 American Academy of Dermatology Annual Meeting, highlighting its significance within the dermatological community.
Switching to Treatment
An intriguing aspect of the latest 52-week data concerns patients who transitioned to the novel oral peptide treatment from a placebo. Those who switched to the therapy at Week 16 were found to achieve complete skin clearance rates by Week 52 that were comparable to patients who had been on the active treatment for the entire 52-week duration. This suggests that initiating the therapy later in the treatment course can still yield substantial and similar long-term benefits, offering flexibility in treatment strategies. This observation is crucial for clinicians and patients alike, indicating that the drug's efficacy is robust and can be harnessed effectively even if treatment initiation is delayed. The ability to catch up to full-year treatment outcomes highlights the potent mechanism of action and the drug's lasting impact on achieving clear skin in plaque psoriasis patients.
Safety and Tolerability
Beyond its impressive efficacy, the long-term safety profile of the targeted oral peptide has been thoroughly examined over the 52-week study period. The adverse event profile observed through Week 52 remained consistent with the safety data collected at earlier time points, specifically Weeks 16 and 24. Crucially, no new safety signals emerged throughout the extended treatment duration. This consistency in safety is a vital indicator for chronic disease management, where long-term tolerability is paramount. Furthermore, when comparing the overall incidence of adverse events and infections, the peptide demonstrated lower rates than another treatment option, deucravacitinib, through Week 24. This suggests a favorable safety margin and a potentially reduced burden of side effects for patients managing plaque psoriasis with this targeted oral therapy.
